Integrase Inhibitors Market Growth Accelerated by Rising Prevalence of HIV

salvepoojacmi

I am salvepoojacmi. I hold full responsibility for this content, which includes text, images, links, and files. The website administrator and team cannot be held accountable for this content. If there is anything you need to discuss, you can reach out to me via pooja.salve@coherentmarketinsights.com email.

Disclaimer: The domain owner, admin and website staff of Times Square Reporter, had no role in the preparation of this post. Times Square Reporter, does not accept liability for any loss or damages caused by the use of any links, images, texts, files, or products, nor do we endorse any content posted in this website.

Integrase Inhibitors Market

The integrase inhibitors market consists of drugs that work by interfering with HIV replication by inhibiting the integrase enzyme, which is essential for viral replication. The integrase inhibitors offer increased potency, limited long term toxicities and higher genetic barrier to resistance compared to other classes of anti-retrovirals.

The global integrase inhibitors market is estimated to be valued at US$ 33.8 Bn in 2024 and is expected to exhibit a CAGR of 10 % over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising prevalence of HIV around the world has been a major driver of growth in the integrase inhibitors market. According to UNAIDS, approximately 38 million people were living with HIV globally in 2020. Sub-Saharan Africa remains the worst affected region, with over 85% of the global new infections occurring here. In 2021, there were an estimated 1.5 million new infections worldwide, along with 650 000 AIDS-related deaths. Integrase inhibitors are now first-line treatments for HIV as they have superior efficacy and resistance profiles compared to earlier drug classes. Their ability to durably suppress viral replication has led to the increasing adoption of these drugs for long term management of HIV infected patients worldwide.

Segment Analysis
The global integrase inhibitors market is dominated by the CCR5 antagonist sub-segment owing to its ability to block HIV from entering and infecting immune cells. CCR5 antagonists effectively block the CCR5 co-receptor, preventing HIV from entering cells. These drugs have demonstrated high viral suppression rates and favorable tolerability profiles. Some of the approved CCR5 antagonist drugs are Pfizer’s maraviroc (Selzentry) and ViiV Healthcare’s ibalizumab (Trogarzo).

Key Takeaways
The global integrase inhibitors market is expected to witness high growth during the forecast period of 2024-2031. Global Integrase Inhibitors Market Size is estimated to reach a value of US$ 33.8 Bn in 2024 and projected to grow at a CAGR of 10% during the forecast period.

Regional analysis: North America dominates the global integrase inhibitors market currently owing to the high HIV prevalence and availability of advanced treatment options in the region. According to UNAIDS, in 2020, around 1.2 million people were living with HIV in the United States. The presence of prominent players and high healthcare expenditure also contribute to the large share of the North American region.

Key players operating in the integrase inhibitors market are Koninklijke TenCate (Netherlands), Low & Bonar (UK), Fibertex Nonwovens (Denmark), Thrace Group (Greece), Huesker (Germany), Berry Global (US), DuPont (US), Strata Systems (US), Leggett & Platt (US), Officine Maccaferri (Italy), GSE Environmental (US), Kaytech (South Africa), Mattex (Saudi Arabia), NAUE (Germany), Propex Operating Company (US), Carthage Mills (US), and Asahi Kasei Advance Corporation (Japan), among others. Pfizer's INSTI bictegravir (Biktarvy) dominates the integrase inhibitors market.

Get More Insights on this Topic- https://www.rapidwebwire.com/integrase-inhibitors-market-demand-forecast-and-growth/